Detalhe da pesquisa
1.
VISTA is an acidic pH-selective ligand for PSGL-1.
Nature
; 574(7779): 565-570, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31645726
2.
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Proc Natl Acad Sci U S A
; 118(26)2021 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172583
3.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Nature
; 515(7528): 577-81, 2014 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428507
4.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Proc Natl Acad Sci U S A
; 114(21): E4223-E4232, 2017 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28484017
5.
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
J Immunol
; 198(4): 1575-1584, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28062694
6.
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.
PLoS Pathog
; 12(1): e1005349, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26741490
7.
Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype.
Cell Immunol
; 323: 49-58, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29103587
8.
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med
; 369(2): 122-33, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724867
9.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
N Engl J Med
; 366(26): 2455-65, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22658128
10.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med
; 366(26): 2443-54, 2012 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22658127
11.
In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice.
J Immunol
; 190(1): 211-9, 2013 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23209326
12.
B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
J Immunol
; 189(1): 39-49, 2012 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22634623
13.
Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3.
J Immunol
; 187(7): 3493-8, 2011 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21873518
14.
Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
Crit Care
; 17(3): R85, 2013 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23663657
15.
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
J Clin Oncol
; 41(4): 715-723, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706735
16.
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
J Transl Med
; 10: 108, 2012 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22640522
17.
The foundations of immune checkpoint blockade and the ipilimumab approval decennial.
Nat Rev Drug Discov
; 21(7): 509-528, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34937915
18.
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.
Cancer Immunol Res
; 10(10): 1175-1189, 2022 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35981087
19.
Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
J Clin Invest
; 132(9)2022 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35316223
20.
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Cancer Res
; 81(11): 2983-2994, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33757978